News | Radiation Therapy | August 19, 2016

Shorter Radiation Course Recommended for Early-Stage Breast Cancer Patients

MD Anderson researchers recommend hypofractionated treatment over conventional approach

August 19, 2016 — Early-stage breast cancer patients receiving a shorter course of whole breast radiation with higher radiation doses per fraction reported equivalent cosmetic, functional and pain outcomes over time as those receiving a longer, lower-dose per fraction course of treatment. These findings were derived from research from The University of Texas MD Anderson Cancer Center.

The study, published in Cancer, found patient-reported functional status and breast pain improved significantly following both radiation schedules, and there were no significant differences in physician-reported cosmetic evaluations. With a more convenient treatment schedule and equivalent outcomes, the authors suggest the shorter course as the preferred option for patients.

In the United States, women historically have been treated with conventionally fractionated whole-breast irradiation (CF-WBI), given in smaller doses over a longer period of time, rather than hypofractionated whole-breast irradiation (HF-WBI), which consists of higher doses for a shorter treatment period.

Large randomized trials from Canada and the United Kingdom have established HF-WBI as a safe and effective treatment for nearly all patients with early-stage breast cancer. In previously published research, the authors showed patients receiving HF-WBI experienced less acute toxicity and post-radiation fatigue compared to those treated with CF-WBI.

However, the adoption of HF-WBI has been limited in the United States. In fact, researchers note only one-third of patients for whom HF-WBI is currently recommended by the American Society of Radiation Oncology (ASTRO) actually receive the shorter course of therapy.

"This trial is particularly important because there is still some hesitation among clinicians in the U.S. about adopting the hypofractionated schedule," said lead author Cameron Swanick, M.D, resident, radiation oncology. "Because American patients tend to have a higher prevalence of obesity, and because prior trials excluded certain patients with high body mass index, there has been this concern that the shorter radiation treatment course may not be as safe for American patients."

For the prospective, unblinded trial, 287 women with stage 0-II breast cancer were randomized to receive either CF-WBI (149 patients) or HF-WBI (138 patients). All women also received a "boost dose," an additional treatment targeting the tumor bed with a higher dose, which has not been systematically analyzed in previous HF-WBI studies.

The trial accrued over half of its patients from the MD Anderson Cancer Network. In addition to MD Anderson, patients were enrolled from the institution's Houston-area locations, Orlando Health (formerly MD Anderson Orlando) in Orlando, Fla., and Banner MD Anderson in Gilbert, Ariz.

"This was the first investigator-initiated randomized trial conducted in the network," said Benjamin Smith, M.D., associate professor of radiation oncology. "It was a success because of the support of our partners and illustrated the potential, promise and power of our network to help achieve our mission."

All participants were at least 40 years of age and previously had been treated with breast-conserving surgery. Seventy-six percent were overweight or obese according to their body mass index. The researchers used validated tools to gather patient-reported outcomes (PROs) on cosmetic, functional and other quality-of-life measures; physicians rated cosmetic results following treatment. Assessments were performed at baseline, six months, and at one, two and three years following treatment.

"There were no significant differences between the treatment arms for any PROs at baseline, six months, one year or three years," said Swanick. "At two years, outcomes from the Functional Assessment of Cancer Therapy Breast trial outcome index were modestly higher in the hypofractionated group."

There were no significant differences in physician-reported cosmetic scores at any time point. Additionally, both patient groups reported similar improvements in breast pain and functional assessments over time.

The researchers continue to follow tumor control outcomes, though no meaningful difference in survival has been found, to date. The study has several limitations, such as a lack of complete data through three years for all patients at the time of last follow-up. All outcomes will be reported once all patients have completed three-year follow-up. Further, patients and physicians were not blinded to treatment arms, which has the potential to bias the reporting outcomes.

The results of this and previous studies further support the use of HF-WBI as the preferred radiation therapy for early-stage breast cancer patients, explained Smith. "At MD Anderson these shorter courses have become the standard of care."

Smith currently leads an ASTRO guideline panel on whole-breast irradiation, and hopes these and other data will support development of evidence-based treatment guidelines for early breast cancer.

In addition to Swanick and Smith, other MD Anderson authors include: Xiudong Lei, Ph.D., Health Services Research; Simona F. Shaitelman, M.D., Pamela J. Schlembach, M.D., Elizabeth S. Bloom, M.D., Eric A. Strom, M.D., Welela Tereffe, M.D., Wendy A. Woodward, M.D., Ph.D., Michael C. Stauder, M.D., and Thomas A. Buchholz, M.D., all of Radiation Oncology; Michelle C. Fingeret, Ph.D., Behavioral Science; and Alastair M. Thompson, M.D., Breast Surgical Oncology. Additional authors include: Tomas Dvorak, M.D., University of Florida Health Cancer Center at Orlando Health.

This work was supported by a Career Development Award from the American Society of Clinical Oncology Conquer Cancer Foundation, funded by the Breast Cancer Research Foundation.

For more information: www.onlinelibrary.wiley.com

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...